对比术后应用促性腺激素释放激素和孕三烯酮治疗子宫内膜异位症患者的临床效果和安全性

摘要

Objective To analyze the safety and efficacy of gestrinone and gonadotropin-releasing hormone therapy in endometriosis patients after surgery.Methods Eighty patients who accepted endometriosis surgery were randomly divided into gestrinone group and gonadotropin-releasing hormone group (n=40 respectively).Clinical efficacy, hormone levels and adverse reactions were compared between groups after treatment.Results The overall response rate of gonadotropin-releasing hormone group (95.00%) was obviously higher than that of gestrinone group (62.50%), the difference was statistically significant (P<0.05).Levels of follicle stimulating hormone, luteinizing hormone, prolactin and estradiol in gonadotropin-releasing hormone group were obviously higher than that of gestrinone group, the difference was statistically significant (P<0.05).Adverse reactions of gonadotropin-releasing hormone group (7.50%) was less than that of gestrinone therapy (35.00%), the difference was statistically significant (P<0.05).Conclusion Gonadotropin-releasing hormone therapy can effectively treat endometriosis and improve hormone levels, which are significantly superior to gestrinone, it is safe and reliable, and has less adverse reactions, suggesting a wide application.%目的 比较子宫内膜异位症术后患者采用孕三烯酮与促性腺激素释放激素治疗的有效性及安全性.方法 选取接受手术治疗的子宫内膜异位症患者80例,按照随机数字表法分为孕三烯酮组与促性腺激素释放激素组各40例,分析两组临床疗效、不良反应以及治疗后体内激素水平情况.结果 促性腺激素释放激素组研究对象的总有效率(95.00%)高于孕三烯酮组(62.50%),差异有统计学意义(P<0.05).促性腺激素释放激素组卵泡刺激素、黄体生成素、催乳素以及雌二醇明显高于孕三烯酮组,差异有统计学意义(P<0.05).促性腺激素释放激素组不良反应发生率(7.50%)低于孕三烯酮组(35.00%),差异有统计学意义(P<0.05).结论 促性腺激素释放激素治疗子宫内膜异位症效果显著,改善患者激素水平,明显优于孕三烯酮,安全可靠,不良反应少,值得推广应用.